Mantle cell lymphoma (MCL) pathogenesis is still partially unexplained. We investigate the importance of microRNA (miRNA) expression as an additional feature that influences MCL pathway deregulation and may be useful for predicting patient outcome. Twenty-three MCL samples, eight cell lines and appropriate controls were screened for their miRNAs and gene expression profiles and DNA copy-number changes. MCL patients exhibit a characteristic signature that includes 117 miRNA (false discovery rate o0.05). Combined analysis of miRNAs and the gene expression profile, paired with bioinformatics target prediction (miRBase and TargetScan), revealed a series of genes and pathways potentially targeted by a small number of miRNAs, including essential pathways for lymphoma survival such as CD40, mitogen-activated protein kinase and NF-jB. Functional validation in MCL cell lines demonstrated NF-jB subunit nuclear translocation to be regulated by the expression of miR-26a. The expression of 12 selected miRNAs was studied by quantitative PCR in an additional series of 54 MCL cases. Univariate analysis identified a single miRNA, miR20b, whose lack of expression distinguished cases with a survival probability of 56% at 60 months. In summary, using a novel bioinformatics approach, this study identified miRNA changes that contribute to MCL pathogenesis and markers of potential utility in MCL diagnosis and clinical prognostication.
Introduction
Mantle cell lymphoma (MCL), a tumor accounting for 6-7% of non-Hodgkin's lymphomas, is distinguished by its resistance to chemotherapy and poor outcome. It originates from follicular mantle zone cells and is characterized by deregulation of multiple survival signaling pathways. [1] [2] [3] It is recognized by the t(11;14)(q13;q32) translocation, which results in cyclin D1 (CCND1) overexpression. [4] [5] [6] Other alterations have been identified, 2 nevertheless, MCL pathogenesis has yet to be fully explained, as the genetic changes so far identified cannot account for the increased survival signaling that characterizes this tumor. 3 In this context, a group of post-transcriptional regulators, the microRNAs (miRNAs), has been proposed as candidates that could complete our understanding of tumor pathogenesis. They are small, noncoding RNAs that regulate the expression of multiple mRNAs 7, 8 and have a key role in the control of the various biological processes involved in cancer pathogenesis. [9] [10] [11] Specific miRNA signatures have been identified for some tumor types, [12] [13] [14] [15] and they are thought to function as metastasis regulators. 16, 17 Altered miRNA expression is also known to have a role in hematopoietic malignancies such as chronic lymphocytic leukemia (miR-15a, miR-16) 18, 19 and diffuse large B-cell lymphoma. 20 Moreover, a recent study has shown that miRNA losses and gains could have a significant role in MCL by regulating CCND1 mRNA expression. 21 In this study, we have explored whether miRNA losses and gains can help explain MCL pathogenesis. We profiled miRNA and mRNA expression in a series of MCL patients and cell lines. miRNAs making up the MCL signature were then related to the MCL mRNA signature through the computational prediction of miRNA targets. Correlation between miRNA expression and patient outcome was also investigated.
Materials and methods

Patients, cell lines and control tissues
The series included 23 frozen MCL lymph nodes (which contain at least 80% of tumoral cells) and 11 reactive lymph nodes (seven) or tonsils (four) for control purposes. Follow-up was obtained for 22 cases. An independent set of 54 formalin-fixed paraffin-embedded MCL diagnostic samples was analyzed for confirmation of survival studies. 22 All the samples were recovered at the time of diagnosis, and MCL diagnosis was performed according to the World Health Organization criteria. 23 The study was carried out under the supervision of the corresponding local ethics committees.
The study also included eight MCL cell lines (REC-1, Jeko, UPN1, UPN2, Granta, Z138, MINO and Hbl2). Sorted mantle-zone B cells (CD19 þ /IgD þ /CD27 À ) 2,3,24 from three routine tonsillectomy samples were used as controls (procedure described in Supplementary text).
Microarray procedures
For miRNA hybridization, 100 ng of total RNA was hybridized on an Agilent 8 Â 15K human miRNA one-color microarray for detecting 470 human and 64 viral miRNAs, following the manufacturer's instructions (Agilent Technologies Inc, Santa Clara, CA, USA). 25 Gene expression was carried out with Agilent Technology microarrays. 26, 27 RNA extraction, details of microarray and hybridization procedures, and gene expression profiling are described in the Supplementary text. miRNA expression profiling. Between-array median normalization was carried out to render miRNA expression data sets comparable. Significantly deregulated miRNAs were computed using Significant Analysis of Microarray analysis (an Excel macro, in this case, that provides q-values directly). 28, 29 The q-value corresponds to the false discovery rate (FDR). 30 miRNAs with FDR o0.05 were taken as being differentially expressed in controls and tumors.
Significant miRNAs (FDR o0.05 and more than twofold up-or downregulation) were represented by a heatmap using SOTArray (http://www.gepas.es).
Associations between miRNAs, gene expression signatures and biological pathways. For each differentially expressed miRNA, a contingency table relating the miRNA and its predicted gene targets (whose probe was included in GE platform, Agilent Technologies Inc) was produced using miRBase Targets Release v. 5.0 (http://www.mirbase.org/; Faculty of Life Sciences, University of Manchester) and TargetScan v. 5.1 (http://www.targetscan.org/; Whitehead Institute for Biomedical Research) (including conserved and nonconserved target sites predictions), taking into account whether these targets were included in a consistent gene expression signature (downregulated targets for upregulated miRNAs and vice versa).
Fisher's exact test was used in the miRBase and TargetScan analyses. Those miRNAs whose Fisher's exact test result indicated an FDR o0.05 were selected for further analysis on the basis of their nonrandom association with the gene expression signature of interest. 31 To identify statistically significant associations between differentially expressed miRNAs (both Significant Analysis of Microarray and Fisher's exact test FDR o0.05) and enriched pathways (FDR o0.26), a ranked list was built that included only the targets predicted for significant miRNAs using the gene expression profiling statistic value obtained from the microarray data. As miRNAs function as repressors, a gain in miRNAs is usually associated with the downregulation of the target RNA or protein, whereas miRNA loss is associated with upregulation of the RNA or protein target. 32 Thus, downregulated miRNAs were tested for their association with upregulated genes, whereas upregulated miRNAs were tested for their association with downregulated genes. The ranked target list was subjected to gene set enrichment analysis (GSEA). 33 Annotations were taken from a curated version of the Biocarta, KEGG and CCG pathway databases 34 with minor modifications (Supplementary Table S1 ). The analysis was carried out independently using miRBase and TargetScan. Only miRNA pathways with significant associations identified by both miRBase and TargetScan predictions were finally considered.
Interaction networks were depicted using Cytoscape bioinformatics software (http://www.cytoscape.org). Figure 1 provides a flowchart of the entire data analytical approach.
Survival analysis
In the first set of 22 patients, Gene Spring software v. 9.0 (Agilent Technologies Inc) was used to normalize miRNA intra-array data at the 75th percentile, as recommended by the manufacturer. 25 Next, a Random Forests algorithm (available from the SIGNS website http://signs.bioinfo.cnio.es/) 26, 35 was used to select a set of 12 miRNAs related to patient survival, which were analyzed in a new set of 54 paraffin-embedded cases for the confirmation step using reverse transcriptase PCR. [36] [37] [38] Univariate Cox regression, available in SPSS v.15.0, (SPSS Inc, Chicago, IL, USA) was used to analyze the confirmation data set. Samples were evaluated for the expression of the 12 miRNAs and other standard clinical features (age, performance status, gender, stage at diagnosis and proliferation activity of the tumor). 39 The comparison of the variables was considered worthwhile in those groups with at least five patients in each category.
Overall survival was plotted by GrapPad Prism software (GraphPad Software, Inc, v. 5, La Jolla, CA, USA) for the Kaplan-Meier method, stratifying the samples into low-and high-risk groups according to the median value of the miR-20b expression. Curves were compared by a log-rank test. miRNA electroporation and immunofluorescence Electroporation. miR-26a and controls (pre-miR-26a and pre-miR-negative control 1, Applied Biosystems) were electroporated at 60 nM concentration using the Neon Transfection System (Invitrogen, Carlsbad, CA, USA) in the MINO and REC-1 cell lines, using the following settings: 1 pulse, 40 ms, 1000 V. Cells were recovered after 24, 48, 72 and 96 h of electroporation.
Reverse transcriptase PCR
Immunofluorescence. Cells were fixed and permeabilized with 100% acetone. p65 (RelA) mouse antibody 1:100 (Santa Cruz Biotechnology, Santa Cruz, CA, USA; SC-8008) was used for primary staining. Secondary antibody staining was carried out with anti-mouse 1:200 (Invitrogen, Alexa Fluor 488). Nuclei were stained with 4,6-diamidino-2-phenylindole (DAPI). Images were obtained by Leica TCS-SP2 (AOBS) confocal microscopy (Leica Microsystems, Germany) with LCS v. 2.61 software (Leica Microsystems).
Results
miRNA profile in MCL cases and MCL-derived cell lines
An miRNA signature for MCL, including all the miRNAs differentially expressed in the 23 MCL cases compared with the 11 reactive lymphoid tissues (FDR o0.05), was identified (Supplementary Table S3 ). It includes 117 human miRNAs: 85 downregulated and 32 upregulated; 56 out of 85 were downregulated (4twofold) and 16 out of 32 were upregulated (4twofold) (Figure 2 ). The most significant miRNAs that were lost in all cases were miR-31, miR-148a and miR-27b (FDR o0.001), whereas the list of upregulated miRNAs was headed by miR-617, miR-370 and miR-654 (FDR o0.001).
Nineteen selected miRNAs were analyzed by qPCR to validate the microarray data further (see Supplementary text).
Eight MCL cell lines were also investigated by comparing their miRNA expression signature with that of CD19 þ /IgD þ / CD27À lymph node-sorted B cells. The miRNA signature (FDR o0.05) identified in MCL cell lines included one upregulated miRNA (4twofold), miR-182, which was also significantly upregulated in MCL cases, and 14 downregulated miRNAs (4twofold) (Supplementary Table S4 ), six of which were also lost in MCL cases, among them miR-26a and miR-150 as already described (Figure 3) .
With less significant FDRs, several components of the let-7 family (f, c, g, e), which are known to regulate multiple stem cell-like properties by silencing multiples targets, including RAS and HMGA2, 40 were downregulated in MCL cases and cell lines. Interestingly, miR-29a and miR-29c, which regulate TCL1A 41 (upregulated in MCL), were lost in the MCL cell lines. MiR-31, which showed one of the greatest losses of all the miRNAs in this series, is predicted to be a regulator of MAP3K14 (NIK) expression, a gene essential for the activation of the alternative NF-kB pathway. 42 A cluster of miRNAs made up of miR-106b, miR-93 and miR-25, and located in 7q22, were significantly upregulated in our MCL series. This cluster functionally overlaps with the mir-17-92 polycistron, 43 ,44 known as oncomir-1. Its amplification in lymphoma and other tumor types has been linked to accelerated c-Myc-induced tumor development by suppression of the expression of the tumor suppressor PTEN and the proapoptotic protein Bim. 45 The gain of function of the miR-106b cluster promotes cell-cycle progression by silencing the cyclin-dependent kinase inhibitor p21/CDKN1A, a direct target of miR-106b. Interestingly, miR-106b overrides a doxorubicin-induced DNA damage checkpoint. 46 Consistent with this finding, many of the MCL cell lines showed stronger expression of the mir-17-92 polycistron.
The series of MCL patients also showed increased expression of miR-372 and miR-373, which are both involved in promoting proliferation and tumorigenesis in primary human cells that harbor active wild-type p53, 47 as found in most MCLs. 2 Finally, miR-210 has been shown to be induced by hypoxia in various tumor types. 48 Association between miRNAs and mRNA signature genes and pathways
To identify statistically significant associations between differentially expressed miRNAs and gene expression signatures, we investigated whether predicted miRNA (FDR o0.05)-mRNA (FDR o0.01) targeting pairs were consistent with the pair Figure 1 Bioinformatics approach to association analyses between miRNAs, mRNA signatures and molecular pathways. To identify statistically significant associations between differentially expressed miRNAs (DEm, FDR o0.05) and gene expression signatures (DEg, FDR o0.05), we tested whether predicted miRNA-mRNA targeting pairs were randomly associated or not. Thus, for each differentially expressed miRNA, we produced a contingency table relating every miRNA and its predicted gene targets, taking into account whether these targets were included in a consistent gene expression signature (downregulated targets for upregulated miRNAs and vice versa). Those miRNAs found to be significant on the basis of the Fisher's exact test (DEm FDR o0.05, but also Fisher's test, FDR o0.05) were selected on the basis of their nonrandom association with the gene expression signature of interest (DEg, FDR o0.01). Gene target predictions for human miRNAs were obtained using miRBase Targets Release v5.0 and TargetScan v5.1. To find statistically significant associations between differentially expressed miRNAs and enriched pathways, we compiled a ranked list including only the targets predicted for significant miRNAs (DEm FDR o0.05, Fisher's exact test FDR o0.05) using the gene expression profiling statistic value (limma moderated t-statistic) obtained from differential expression analysis. Next, a gene set enrichment method (GSE, for example, GSEA) was applied using the ranked target list. Thus, pathways enriched in targets of the selected miRNAs are revealed (GSE, FDR o0.26). Using this approach, the experimental microarray gene expression data are inferred to predict the effects of miRNA expression on the global behavior of the biological pathways.
Mantle cell lymphoma miRNAs L Di Lisio et al component inverse regulation, and whether the consistent pairs were nonrandomly associated. Gene expression results proceeding from the hybridization of 23 MCL samples and 11 controls (lymph nodes and tonsils) are reported in Supplementary text and Supplementary Table S5 .
Target genes predicted with miRBase and TargetScan software were listed and Fisher's exact test was applied to significant miRNAs. miRBase and TargetScan jointly identified 21 downregulated and 4 upregulated miRNAs with FDR o0.05 on the basis of a significant results of Fisher's exact tests (Results in Supplementary Tables S6-S8 and Supplementary  text) .
At this point, connections between the miRNA signatures and the MCL-deregulated pathways were also examined using GSEA. Thus, miRNAs found to be significant by Fisher's exact test were matched with the target genes predicted by miRBase and TargetScan and grouped by significantly enriched GSEA pathways (FDR o0.26). A ranked list containing 3712 nonredundant upregulated genes predicted by miRanda (http:// www.mirbase.org; Faculty of Life Sciences, University of Manchester) as targets for the downregulated miRNAs was used. The same approach was adopted for TargetScan predictions using a preranked list of 3861 nonredundant upregulated genes. While using GSEA with upregulated miRNAs, we followed the inverse approach, building a ranked list of predicted downregulated targets (537 miRanda targets and 1951 TargetScan targets).
Results are included in Table 1, Supplementary Table S9 and illustrated in Figure 4 . The most remarkable upregulated pathways associated with losses of miRNAs targeting the genes included in the corresponding pathway were those of the CD40, NF-kB and mitogen-activated protein kinase (MAPK) pathways (and Supplementary Figure S1 ). We also performed GSEA using the whole gene expression list instead of target-oriented lists. We identified up to 23 significant gene sets related to MCLs, including three out of six gene sets whose expression seems to be closer to miRNA activity.
Interestingly, differentially expressed miRNAs that were significantly associated with gene expression profiles, as revealed by Fisher's exact test, were also capable of targeting more than one gene included in these pathways, which suggests a direct regulatory role in the aforementioned pathways.
No significant relations were found between upregulated miRNAs and downregulated pathways.
miRNA functional validation
MiR-26a was downregulated in MCL cases and cell lines. It was also significant in Fisher's exact test and in pathway analysis, thus it was chosen for functional validation. One of its predicted targets of greatest interest was MAP3K2. This was found to be upregulated in our samples and is already known as an NF-kB pathway-activating kinase. 49 NF-kB activation is a common and important finding in MCL cells, but the mechanism of activation is still essentially unknown.
The MINO and REC-1 MCL cell lines proved to be the best model for validation experiments because they have very low levels of miR-26a expression coupled with NF-kB activation, as demonstrated by RelA (p65) nuclear translocation: a finding commonly observed in MCL cases. MiR-26a and negative control hsa-miR-182 hsa-miR-26a hsa-miR-28 hsa-miR-151 hsa-miR-380-3p hsa-miR-223 hsa-miR-29c hsa-miR-768-3p hsa-miR-768-5p hsa-miR-30e-5p hsa-miR-150 hsa-miR-195 hsa-miR-29a hsa-miR-146b hsa-miR-222 
Clinical variability
To identify miRNAs of potential clinical prognostic value, miRNA microarray data of 22 MCL cases were analyzed with the Random Forest predictor. [36] [37] [38] The analysis yielded a set of miRNAs that gave a Kaplan-Meier survival curve (log-rank Po0.001) in which 12 miRNAs were statistically significant (Po0.05) (Supplementary Table S10 ). These miRNA were selected to confirm their expression in a second group of 54 formalin-fixed paraffin-embedded cases by quantitative reverse transcriptase PCR. MiR-198 was excluded from the analysis because it had a low efficiency of amplification in qPCR. After endogenous normalization, ÀDC t values were used for overall survival analysis by Cox regression using SPSS v. 15.0. Univariate Cox regression analysis confirmed the significance of miR-20b as a prognostic marker (P ¼ 0.013) ( Table 2) , whereas other clinical variables (age o60 years, P ¼ 0.499; gender, P ¼ 0.592; performance status, P ¼ 0.916; clinical stage at diagnosis, P ¼ 0.743; and proliferation activity of the tumor, P ¼ 0.317) were found not to be the significant prognostic markers for survival in this group. Results were plotted in a Kaplan-Meier survival curve (log-rank P ¼ 0.032) (Figure 6 ), dividing the samples into two risk groups according to their median miR-20b expression. Cases lacking miR-20b expression had a survival probability of 56% at 60 months, whereas only 33% of patients included in the high-risk group (high level of expression of miR-20b) survived for 460 months.
Discussion
Gene expression profiling studies of MCL have revealed increased survival signaling, 2,3,50 but have not identified the mechanisms responsible. miRNA profiling identifies additional genes whose deregulation may enable us to explain MCL pathogenesis more fully, as indicated by the gene pathways targeted by the deregulated miRNAs. CD40, MAPK and NF-kB are among the most significantly deregulated pathways whose increased expression is known to be relevant in MCL pathogenesis. 1 In addition, MCL has a downregulated GC signature (including BCL6, LMO2, SERPIN9 and GCET2 genes) coupled with increased expression of the miRNAs targeting these genes. This suggests that absence of GC differentiation by MCL cells could depend on changes in the expression of multiple miRNAs that regulate the GC signature.
The most essential pathways and genes identified here are potentially targeted simultaneously by multiple miRNAs, suggesting that transcriptional regulation by miRNAs in MCL is the result of the concurrent deregulation of multiple miRNAs with similar targets. This is consistent with what is known about the role of miRNAs as fine-tuning regulators. 51 Deregulation of the MAPK pathway is one of the cardinal findings in MCL, presumably in relation to CD40 signaling, as shown by this gene expression analysis and other functional studies. 3, 52 These findings indicate that constitutive CD40 signaling in B cells selectively activates the noncanonical NF-kB pathway 53 and the MAP kinases, JNK and ERK. The data presented here show that the miRNAs deregulated in MCL characteristically target the CD40 signaling pathway and MAPK genes.
Most of these changes have been detected in MCL cases and MCL cell lines, although there are some intriguing minor variations. MCL cell lines showed gain of oncomir-1 (17-92 polycistron), confirming previous observations in the Jeko1 cell line. 54 In contrast, MCL cases showed increased expression of the miRNAs miR-106b, miR-93 and miR-25, which are functionally homologous to the 17-92 polycistron, known as oncomir-1.
55 MCL cell lines are more representative of the blastoid form than of classic MCL, thus we may hypothesize that aggressive transformation is accompanied by changes in the expression of the miRNAs included in the 17-92 polycistron.
Some of these results coincide with other recently published findings in MCL, such as the increased expression of miR-124a, miR-155, miR-302c, miR-345, miR-373* and miR-210, together with loss of miR-150 and miR-142-3p (the latter with a less significant FDR). 56, 57 Selected results have been functionally validated. Thus, the restoration of miR-26a expression in the Mino and Rec-1 cell lines inhibited RelA nuclear translocation at 72 and/or 96 h, which is consistent with there being an indirect effect of the MAPK pathway and, in particular, of MAP3K2 protein on NF-kB activation. Interestingly, miR-26a, whose expression in normal mantle cells is confirmed by other groups, 58 is already known to have a role in other types of cancer. 59, 60 These data also identify potential new diagnostic and prognostic markers. MCL diagnosis requires some additional tools to enable CCND1-negative forms and blastic variants to be better recognized. In addition, MCL response to therapy is not uniformly unfavorable, and some MCL cases follow a relatively indolent clinical course. Interestingly, weak miR-20b expression can be useful for predicting clinical behavior, enabling a group of MCLs with higher survival probability to be distinguished. MiR-20b expression has been found to have a role in other type of cancers, [61] [62] [63] in which its high level of expression was associated with a worse prognosis, as is the case for what we found in MCL. It should be noted that miR-20b is localized in a cluster (X chromosome) that shares some similarities with oncomir-1, which is already known to be strongly expressed in MCL cell lines, and is homologous at 21 out of 23 nucleotides with miR-20a, a member of the aforementioned cluster. Abbreviations: HR, hazard ratio; miRNA, microRNA. Cox regression models: validation group, 54 samples. Individual results of Cox univariate regression models using the 11 miRNAs are shown, including P-value and HRs. Only miR-20b was significant (P ¼ 0.013).
Figure 6
Correlation between miR20b expression and overall survival: confirmation group of 54 cases. Cox regression model was derived from the univariate analysis. The Kaplan-Meier survival curve (log-rank P ¼ 0.032) was calculated by stratifying the 54 samples into two subgroups according to median expression of the miR-20b. This function estimated a 56% survival rate at 60 months.
The miRNA changes detected here can be explained only in a few cases by chromosomal gains and losses such as the loss of miR-31 (9p21), although the results were not significant (data not shown). Other researchers have already demonstrated that only the levels of miRs included in the miR-17-92 cluster were significantly related to genetic alterations at 13q31. 56 It is therefore likely that most of the changes require other explanations, such as epigenetic regulation or oncogene targeting.
These results are in accordance with those showing that individual and miRNA clusters regulate gene expression with overlapping patterns. 64 It is important to emphasize that the approach followed here, looking at the association of mRNA and miRNA expression, accounts for only a part of the ability of miRNA to modulate protein expression; as miRNA also regulates mRNA translation. However, these findings are consistent with others showing that mRNA destabilization is usually the main component of repression in more highly regulated targets 64 and the same approach can be used to investigate others malignancies. These results also identify miRNAs that could be targeted in future therapeutic experiments and suggest miR-20b as an important component in MCL survival to investigate more in depth.
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